Overview
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Eligibility
Inclusion Criteria:
- Has voluntarily agreed to participate in this clinical trial.
- Adults over 19 years of age
- Diagnosed with type 2 diabetes
Exclusion Criteria:
- Has severe renal and liver disorders
- Has type 1 diabetes
- Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study
- Those who are deemed ineligible to participate in the study by the investigator


